Johnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission

Rhea-AI Summary

Johnson & Johnson (NYSE: JNJ) launched Generation Fine on May 7, 2026, a global campaign to encourage patients with major depressive disorder (MDD) to seek remission rather than accept being "fine."

Campaign is based on a global survey: nearly 4 in 5 patients doubt antidepressants will achieve remission; about 2 in 3 report ongoing symptoms. Generation Fine partners with Mental Health America, features patient stories and advocates, and provides resources to support conversations with healthcare providers.

AI-generated analysis. Not financial advice.

Positive

• Survey finds nearly 4 in 5 patients doubt full remission
• Campaign partners with Mental Health America
• Includes patient stories and public advocates to reduce stigma
• Provides resources to support patient–provider conversations

Negative

• 2 in 3 patients report residual depressive symptoms while on treatment
• Almost 90% say symptoms affect workplace functioning
• 40% of patients haven't raised concerns due to low energy/time
• Advocates and organizations were compensated by Johnson & Johnson

News Market Reaction – JNJ

-0.94%

1 alert

-0.94% News Effect

On the day this news was published, JNJ declined 0.94%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Global MDD prevalence: 332 million people U.S. MDD prevalence: More than 22 million adults Survey geography: 7 countries, 4 continents +5 more

8 metrics

Global MDD prevalence 332 million people Estimated worldwide major depressive disorder burden

U.S. MDD prevalence More than 22 million adults Adults in the U.S. living with major depressive disorder

Survey geography 7 countries, 4 continents Scope of Generation Fine global survey of patients and providers

Residual symptoms on treatment About 2 in 3 people People with MDD who continue to experience depressive symptoms on treatment

Impact on everyday life Almost 3 in 4 patients Survey respondents reporting residual symptoms affect everyday life

Work impairment Nearly 90 percent Patients reporting symptoms affect how they show up at work

Provider discussion barriers 40 percent Patients who had not raised concerns due to lack of time or energy

Provider solution skepticism One-third of patients Those who do not think providers will have solutions for ongoing symptoms

Market Reality Check

Price: $226.79 Vol: Volume 7,362,825 is close...

normal vol

$226.79 Last Close

Volume Volume 7,362,825 is close to the 20-day average of 7,802,708, suggesting typical trading interest ahead of this campaign-focused news. normal

Technical Shares trade above the 200-day MA, with price at 224.62 versus a 207.19 200-day average.

Peers on Argus

JNJ is down 0.41% while large-cap peers show a mixed pattern: ABBV and LLY are m...

JNJ is down 0.41% while large-cap peers show a mixed pattern: ABBV and LLY are modestly negative, AZN and NVS slightly positive, and NVO weaker. No peers appear in the momentum scanner and there are no same-day peer headlines, pointing to a stock-specific reaction to company developments rather than a coordinated sector move.

Historical Context

5 past events · Latest: May 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 05	Phase 2b IBD data	Positive	+0.6%	JNJ-4804 Phase 2b showed higher remission and endoscopic response vs comparators.
May 05	Phase 3 Crohn’s data	Positive	+0.6%	TREMFYA met primary endpoint in perianal fistulizing Crohn’s with significant remission rates.
May 05	Robotic system study	Positive	+0.6%	OTTAVA robotic system met safety and performance endpoints in 30-patient gastric bypass study.
May 04	MDD meta-analysis	Positive	-1.3%	CAPLYTA ranked highest across several efficacy measures in adjunctive MDD network meta-analysis.
Apr 30	IR leadership change	Positive	+1.1%	Appointment of Ryan Koors as Vice President, Investor Relations with 20+ years at JNJ.

Pattern Detected

Recent JNJ news with positive clinical or strategic content has usually aligned with modest positive price moves, with only one divergence on a psychiatry-focused update.

Recent Company History

Over the last week, Johnson & Johnson has reported several clinically focused milestones and corporate updates. On May 5, Phase 2b data for JNJ‑4804 in inflammatory bowel disease and Phase 3 FUZION results for TREMFYA in perianal fistulizing Crohn’s disease coincided with +0.6% moves. A pivotal 30‑patient OTTAVA robotic surgery study and an Investor Relations leadership change also aligned with small gains. The CAPLYTA adjunctive MDD meta-analysis on May 4 saw a -1.32% reaction, contrasting with today’s broader depression-focused awareness campaign.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-11

An effective S-3ASR shelf dated 2026-02-11 permits Johnson & Johnson to issue unsecured debt securities from time to time under an existing indenture. Terms such as interest structure and maturity will be set in future prospectus supplements, with net proceeds earmarked for general corporate purposes including working capital, capital expenditures, buybacks, refinancing, and acquisitions.

Market Pulse Summary

This announcement introduces Generation Fine, a global effort by Johnson & Johnson to reframe expect...

Analysis

This announcement introduces Generation Fine, a global effort by Johnson & Johnson to reframe expectations in major depressive disorder and highlight remission as a treatment goal. With survey data across 7 countries and a burden affecting 332 million people worldwide, it reinforces the scale of unmet need rather than adding new clinical results. In context of recent MDD and neuroscience updates, key metrics to watch remain future trial readouts, real-world uptake of depression treatments, and any follow-on regulatory or commercial disclosures.

Key Terms

major depressive disorder, MDD, remission

3 terms

major depressive disorder medical

"nearly 4 in 5 patients living with major depressive disorder don't believe"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

MDD medical

"MDD, or clinical depression, is one of the most common psychiatric disorders"

Major depressive disorder (MDD) is a medical condition characterized by persistent low mood, loss of interest in daily activities, and impaired functioning similar to carrying a heavy backpack that makes ordinary tasks much harder. For investors, MDD matters because treatments and therapies for it are a large market regulated by health authorities; clinical trial outcomes, approvals, or safety concerns can strongly affect a drugmaker’s sales prospects, valuation, and risk profile.

remission medical

"don't believe antidepressants will help them reach remissionCampaign draws on expertise"

Remission is a medical state where signs and symptoms of a disease have lessened or disappeared, which can be temporary or lasting and may be described as partial or complete. For investors, remission outcomes in clinical trials or patient care signal how well a treatment works and influence a drug’s market potential, future sales, regulatory approval chances and stock valuations — similar to seeing a storm clear and assessing whether the weather will stay fair.

AI-generated analysis. Not financial advice.

Generation Fine launches after global survey finds nearly 4 in 5 patients living with major depressive disorder don't believe antidepressants will help them reach remission

Campaign draws on expertise of Mental Health America and elevates the voices of leading mental health advocates, including Kyle Long, television studio analyst, retired National Football League (NFL) player

NEW BRUNSWICK, N.J., May 7, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the launch of Generation Fine, a global campaign designed to challenge what it means to feel "fine" in depression care and empower patients to take the first step in moving beyond "good enough" by talking with their healthcare provider. Informed by a global survey of patients and healthcare providers spanning seven countries and four continents, the campaign reflects a troubling reality: nearly 4 in 5 patients living with major depressive disorder (MDD) don't believe antidepressants will help them reach remission. Developed in collaboration with leading mental health advocates and drawing on the expertise of Mental Health America, Generation Fine highlights the unique challenges and experiences of people living with depression and provides valuable resources to support more productive conversations about their care—including the possibility of remission.

"Depression doesn't look the same for everyone, but it is often treated with the same one-size-fits-all approach," said Jessica Jackson, Ph.D., Vice President of Alliance Development, Mental Health America. "This disconnect can leave people feeling unseen or misunderstood, while stigma and societal pressures make it even harder to seek help. We need to change the conversation and create opportunities where all people feel empowered to say, 'I'm not okay.'"

MDD, or clinical depression, is one of the most common psychiatric disorders, affecting an estimated 332 million people worldwide.^1,2 In the U.S. alone, more than 22 million adults live with the disorder.³ While oral antidepressants work for some, studies show that about 2 in 3 people living with MDD continue to experience residual or ongoing depressive symptoms while on treatment.⁴ Unfortunately, this means many patients are left settling for outcomes that are just "fine."

The Generation Fine global survey findings underscore the everyday burden of ongoing symptoms people with MDD continue to face while on treatment:

• Feeling "fine" on treatment is accepted as good enough: Nearly 4 in 5 patients believe antidepressants are unlikely to address all of their symptoms or help them reach remission.
• Ongoing depression symptoms are a significant burden: Almost 3 in 4 patients said their residual symptoms have a real impact on their everyday life. Nearly 90 percent reported their symptoms affect how they show up at work, and more than half said they isolate themselves from others more frequently than they normally would because of how they're feeling.
• Patients struggle to talk to their healthcare provider about residual symptoms: Of those who hadn't raised concerns with their provider, 40 percent said they don't have the time or energy to initiate the conversation, and one-third don't think their provider will have a solution to help address their ongoing symptoms.

"These findings reinforce what patients have been telling us for years: far too many continue to struggle despite being on treatment," said Peter Fang, Worldwide Vice President, Neuroscience, Global Commercial Strategy Organization, Johnson & Johnson. "No one should have to settle for 'fine' when it comes to their care, which is why Johnson & Johnson is committed to redefining what's possible for people living with MDD. With Generation Fine, we aim to empower patients and equip them with the tools, resources and confidence to talk to their healthcare providers about moving beyond 'fine' and toward remission from their depression."

At the heart of the campaign are authentic patient stories that reflect the unique challenges and experiences of people living with and managing depression, underscoring how different depression looks for everyone. By sharing these stories, Generation Fine seeks to help patients feel less alone in their experience, encourage them to expect more from treatment and empower them to take the first step in talking to their healthcare provider.

"I've battled depression at different stages of my life, including during my career in the NFL, and for a long time I felt like I had to 'tough it out' and handle it by myself," said Kyle Long, NFL Alum and former Chicago Bears Offensive Lineman. "When I stopped trying to fight it alone and started being honest with myself and my support system, including my doctor, everything changed. Speaking up about what you're feeling isn't weakness—it's the strongest play you can make."

"As someone who has navigated my own depression journey, I know firsthand how frustrating it can be when a treatment doesn't work or address all your symptoms," said Jessi Gold, M.D., M.S., psychiatrist and Generation Fine ambassador. "In that moment, it's easy to settle because the idea of adjusting your treatment plan can feel overwhelming. I want patients to know they're not alone in this struggle and that they deserve to feel better than 'fine'—because 'fine' is not the finish line."

To learn more and join a global conversation about looking beyond "fine" and toward a goal of remission with depression care, visit Generation-Fine.com.

All content creators, mental health advocates and Mental Health America were compensated by Johnson & Johnson for their collaboration on this campaign.

ABOUT THE GENERATION FINE GLOBAL SURVEY
As part of Generation Fine, Johnson & Johnson conducted a global survey spanning seven countries (U.S., Brazil, Canada, China, Germany, Italy and Spain) to better understand the invisible burden of ongoing symptoms people with major depressive disorder (MDD) face while on treatment. The online communications poll, fielded by Wakefield Research from August 6-17, 2025, surveyed 850 adults currently managing their MDD with oral antidepressants and 800 healthcare providers who treat patients with MDD. Mental Health America reviewed the survey results in advance of publication and received compensation for their review.

ABOUT MAJOR DEPRESSIVE DISORDER (MDD)
MDD is one of the most common psychiatric disorders and a leading cause of disability worldwide, impacting an estimated 332 million people—or about 5 percent of the adult population.¹ In the U.S. alone, an estimated 22 million adults are living with MDD.³ While depression is typically treated with a "one-size-fits-all" approach, no two cases are the same. MDD is a complex, heterogeneous disorder involving multiple regions of the brain and presenting with as many as 256 unique symptom combinations.⁵ As a result, responses to treatment vary widely. With current standard-of-care oral antidepressants, about 2 in 3 MDD patients continue to experience residual or ongoing symptoms.⁴ Moreover, MDD is a risk factor for the development and worsening of a range of comorbidities, illustrating the importance of integrating mental and general health care.⁶

ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and where solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. 

Learn more at https://www.jnj.com/ or at https://innovativemedicine.jnj.com/.

© Johnson & Johnson and its affiliates 2026. All rights reserved.

Footnotes

1. World Health Organization. Depressive disorder (depression). Accessed September 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/depression.
2. Depression and Bipolar Support Alliance. Types of depression. Accessed September 2025. Available at: https://www.dbsalliance.org/education/depression/types-of-depression/.
3. Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Accessed November 2025.
4. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.1176/ajp.2006.163.11.1905.
5. Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology. 2021 Jan;46(1):156-175. doi: 10.1038/s41386-020-00789-3. Epub 2020 Aug 11. PMID: 32781460; PMCID: PMC7688954.
6. Zhu L et al. Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. J Manag Care Spec Pharm. 2022;28(11-a suppl):S2–S13. doi: 10.18553/jmcp.2022.28.11-a.s1.

Media contact: Caitlin Lormel Johnson & Johnson clormel@its.jnj.com

Investor contact: Jess Margevich Johnson & Johnson investor-relations@its.jnj.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-launches-generation-fine-a-new-movement-encouraging-patients-to-expect-more-from-depression-treatment-and-aim-for-remission-302764753.html

SOURCE Johnson & Johnson

FAQ

What is Generation Fine and why did Johnson & Johnson (JNJ) launch it?

Generation Fine is a global campaign encouraging patients to seek remission beyond feeling "fine." According to Johnson & Johnson, the campaign responds to survey findings that many people with MDD experience ongoing symptoms and doubt current treatment will deliver remission.

What did Johnson & Johnson say the global survey found about antidepressant effectiveness?

The survey found nearly 4 in 5 patients believe antidepressants are unlikely to achieve remission. According to Johnson & Johnson, the finding motivated Generation Fine to promote conversations about treatment adjustments and remission goals with providers.

How does Generation Fine support patients with major depressive disorder (MDD)?

Generation Fine offers patient stories, educational resources, and tools to guide discussions with clinicians. According to Johnson & Johnson, the campaign aims to empower patients to raise concerns and explore treatment options toward remission.

Which organizations and advocates are involved with Generation Fine (JNJ)?

Generation Fine collaborates with Mental Health America and features mental health advocates like Kyle Long. According to Johnson & Johnson, these partnerships shape campaign content and amplify patient voices globally.

What survey statistics from Generation Fine highlight barriers to care?

Key findings: about 2 in 3 report residual symptoms, almost 90% report work impacts, and 40% avoid raising concerns due to low energy/time. According to Johnson & Johnson, these stats underline communication gaps between patients and providers.